I am the Vice President of Technology and General Manager at OpenCell Technologies, Inc. in St. Louis, Missouri focusing on translating benchtop microfluidics to cell and gene therapy. I specialize in the development of diagnostic devices, the synthesis of complex biologics, and the design of biomimetic microchannels. In 2019, I received my Ph.D. in Mechanical Engineering for my work on the development of a novel method for antibody conjugate synthesis and detection of COPD biomarkers. 

After graduation, I worked as a biostatistician in the Department of Neurology and Emergency Medicine at Washington University School of Medicine in St. Louis using imaging markers acquired through MRI to assess risk factors for the development of ischemia in pediatric sickle cell patients. During this time, I oversaw the statistical analysis of two clinical trials in SARS-CoV-2 detection and cerebral vessel reactivity in children with sickle cell anemia.  

I have over 10 years of experience in the design of nano- and microfluidic devices and 7 years of experience in data science/statistics. During this time I have authored and co-authored over 30+ journal publications.